Compare Amylx Pharmaceuticals Inc (AMLX) vs Barrick Gold Corp (B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Barrick Gold Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Barrick Gold Corp trades at $40.13 (market cap $68.49B). The key difference: Barrick Gold Corp is far larger — about 27.1× Amylx Pharmaceuticals Inc's market cap, and Barrick Gold Corp pays a 1.71% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | B | |
|---|---|---|
Market Cap | $2.53B | $68.49B |
Sector | Health | Basic Materials |
52-Week High | $24.19 | $52.97 |
52-Week Low | $7.82 | $22.83 |
Enterprise Value | $2.28B | $66.08B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Barrick Mining (B) trades at $43.69, up 5.49% in 24 hours, with a bullish technical outlook and strong fundamentals. Recent earnings beats, a $1.95 billion settlement with Newmont, and a robust cash flow trend highlight operational strength. The stock is near its consensus price target of $50.17, supported by a 66.67% analyst buy rating.
The outlook is positive due to earnings growth, favorable valuations, and strategic initiatives like the North American IPO. Risks include gold price volatility and execution of expansion plans. Upside potential exists if the company maintains its earnings momentum and capitalizes on gold market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
